nogrЭкспериментальная и клиническая гастроэнтерологияExperimental and Clinical Gastroenterology1682-8658«Global Media Technologies»10.31146/1682-8658-ecg-214-6-39-46nogr-2305Research ArticleКЛИНИЧЕСКАЯ ГАСТРОЭНТЕРОЛОГИЯCLINICAL GASTROENTEROLOGYРоль В-лимфоцитов и плазматических клеток в патогенезе воспалительных заболеваний кишечникаThe role of B-lymphocytes and plasma cells in the pathogenesis of inflammatory bowel diseaseshttps://orcid.org/0000-0003-4860-0112ХлыноваО. В.KhlynovaO. V.noemail@neicon.ruhttps://orcid.org/0000-0002-0853-925XКосареваП. В.KosarevaP. V.perm-bagira@yandex.ruФадеевД. С.FadeevD. S.noemail@neicon.ruСиваковаЛ. В.SivakovaL. V.noemail@neicon.ruhttps://orcid.org/0000-0002-0976-8863СамоделкинЕ. И.SamodelkinE. I.noemail@neicon.ruФедеральное государственное бюджетное образовательное учреждение высшего образования «Пермский государственный медицинский университет имени академика Е. А. Вагнера» Министерства здравоохранения Российской ФедерацииРоссияPerm State Medical University n. a. E. A. Wagner of the Ministry of Health of the Russian FederationRussian FederationФГАОУ ВО «Пермский государственный национальный исследовательский университет»РоссияPerm State UniversityRussian FederationГБУЗ ПК «КБ Свердловского района»РоссияClinical hospital of the Sverdlovsk regionRussian FederationФедеральное государственное бюджетное образовательное учреждение высшего образования «Пермский государственный медицинский университет имени академика Е. А. Вагнера» Министерства здравоохранения Российской Федерации; ФГАОУ ВО «Пермский государственный национальный исследовательский университет»РоссияPerm State Medical University n. a. E. A. Wagner of the Ministry of Health of the Russian Federation; Perm State UniversityRussian Federation202325072023063946Copyright © Хлынова О.В., Косарева П.В., Фадеев Д.С., Сивакова Л.В., Самоделкин Е.И., 20232023Хлынова О.В., Косарева П.В., Фадеев Д.С., Сивакова Л.В., Самоделкин Е.И.Khlynova O.V., Kosareva P.V., Fadeev D.S., Sivakova L.V., Samodelkin E.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.nogr.org/jour/article/view/2305

Цель: Изучить литературу относительно роли В-лимфоцитов и плазматических клеток в патогенезе болезни Крона (БК) и язвенного Колита (ЯК). Материалы и методы: Проанализировано 86 литературных источников из баз данных Scopus, Web of Science, Google scholar, PubMed, а также находящихся в свободном доступе в Google. Результаты. БК и ЯК являются серьезной проблемой здравоохранения в связи с широкой распространенностью, объективными трудностями лечения, обусловленных сложностью патогенеза и продолжающимся поиском эффективных лекарственных препаратов. На сегодняшний день наиболее успешными методами патогенетической терапии считается терапия антицитокинами и использование лекарственных средств, направленных на подавление Т-клеточного ответа. Заключение. Показано, что при использовании существующих методов лечения у части пациентов они не эффективны. Изучение В-лимфоцитов и плазматических клеток собственной пластинки слизистой оболочки кишки как возможной терапевтической мишени при лечении ЯК и БК является актуальным.

Objective: To study the literature on role of B-lymphocytes and plasma cells in the pathogenesis of Crohn’s disease (CD) and ulcerative colitis (UC). Materials and methods: We analyzed 86 literature sources from the Scopus, Web of Science, Google scholar, PubMed databases, as well as those that are freely available on Google. Results. CD and UC are a serious public health problem due to their wide prevalence, objective difficulties in treatment due to the complexity of pathogenesis and the ongoing search for effective drugs. To date, the most successful methods of pathogenetic therapy are anticytokines and the use of drugs aimed at suppressing the T-cell response. Conclusion. It is shown that when using existing methods of treatment in some patients, they are not effective. The study of B-lymphocytes and plasma cells of the lamina propria of the intestinal mucosa as a possible therapeutic target in the treatment of UC and CD is relevant.

воспалительные заболевания кишечникаВ-лимфоцитыплазматические клеткиinflammatory bowel diseaseB-lymphocytesplasma cellsReferencesChou J-W., Lai H-C., Chang C-H. et al. Epidemiology and Clinical Outcomes of Inflammatory Bowel Disease: A Hospital-Based Study in Central Taiwan. Gastroenterol Res Pract. 2019 Jun 13;2019:4175923. doi: 10.1155/2019/4175923.Chou J-W., Lai H-C., Chang C-H. et al. Epidemiology and Clinical Outcomes of Inflammatory Bowel Disease: A Hospital-Based Study in Central Taiwan. Gastroenterol Res Pract. 2019 Jun 13;2019:4175923. doi: 10.1155/2019/4175923.Pasvol T.J., Horsfall L., Bloom S., Segal A. W., Sabin C., Field N., Rait G. Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study. BMJ Open. 2020 Jul 19;10(7): e036584. doi: 10.1136/bmjopen-2019-036584.Pasvol T.J., Horsfall L., Bloom S., Segal A. W., Sabin C., Field N., Rait G. Incidence and prevalence of inflammatory bowel disease in UK primary care: a population-based cohort study. BMJ Open. 2020 Jul 19;10(7): e036584. doi: 10.1136/bmjopen-2019-036584.Osikov M. V., Simonyan E. V., Listik E. V., Bakeeva A. E., Bivalkevich V. A. Inflammatory bowel disease: choosing of the optimal experimental model. Modern problems of science and education. 2017; (3) Available at: https://science-education.ru/ru/article/view?id=26524&ysclid=lb4wqditj1291559416 Access 05.01.2023.@@ Осиков М. В., Симонян Е. В., Листик Е. В., Бакеева А. Е., Бивалькевич В. А. Воспалительные заболевания кишечника: выбор оптимальной экспериментальной модели. Современные проблемы науки и образования. - 2017; - № 3: https://science-education.ru/ru/article/view?id=26524&ysclid=lb4wqditj1291559416Osikov M. V., Simonyan E. V., Listik E. V., Bakeeva A. E., Bivalkevich V. A. Inflammatory bowel disease: choosing of the optimal experimental model. Modern problems of science and education. 2017; (3) Available at: https://science-education.ru/ru/article/view?id=26524&ysclid=lb4wqditj1291559416 Access 05.01.2023.@@ Осиков М. В., Симонян Е. В., Листик Е. В., Бакеева А. Е., Бивалькевич В. А. Воспалительные заболевания кишечника: выбор оптимальной экспериментальной модели. Современные проблемы науки и образования. - 2017; - № 3: https://science-education.ru/ru/article/view?id=26524&ysclid=lb4wqditj1291559416Gorelov A. V., Kanner E. V. Inflammatory bowel diseases in children: peculiarities of the disease course and therapy. Meditsinskiy sovet = Medical Council. 2018;(2):140-145. (In Russ.) doi: 10.21518/2079-701X-2018-2-140-145.@@ Горелов А. В., Каннер Е. В. Воспалительные заболевания кишечника у детей: особенности течения и терапии. Медицинский совет. 2018; 2: 140-145.Gorelov A. V., Kanner E. V. Inflammatory bowel diseases in children: peculiarities of the disease course and therapy. Meditsinskiy sovet = Medical Council. 2018;(2):140-145. (In Russ.) doi: 10.21518/2079-701X-2018-2-140-145.@@ Горелов А. В., Каннер Е. В. Воспалительные заболевания кишечника у детей: особенности течения и терапии. Медицинский совет. 2018; 2: 140-145.Glavnov P. V., Lebedeva N. N., Kashchenko V. A., Varzin S. A. Ulcer colitis and crohn’s disease. current state of a problem of an etiology, early diagnostics and treatment (review of literature). Vestniks of Saint Petersburg University. 2015; 11(4): 48-72. (in Russ.)@@ Главнов П. В., Лебедева Н. Н., Кащенко В. А., Варзин С. А. Язвенный колит и болезнь Крона. Современное состояние проблемы этиологии, ранней диагностики и лечения (обзор литературы). Вестник СПбГУ. 2015; 11(4): 48-72.Glavnov P. V., Lebedeva N. N., Kashchenko V. A., Varzin S. A. Ulcer colitis and crohn’s disease. current state of a problem of an etiology, early diagnostics and treatment (review of literature). Vestniks of Saint Petersburg University. 2015; 11(4): 48-72. (in Russ.)@@ Главнов П. В., Лебедева Н. Н., Кащенко В. А., Варзин С. А. Язвенный колит и болезнь Крона. Современное состояние проблемы этиологии, ранней диагностики и лечения (обзор литературы). Вестник СПбГУ. 2015; 11(4): 48-72.Porter R.J., Kalla R., Ho G. T. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res. 2020 Apr 24;9: F1000 Faculty Rev-294. doi: 10.12688/f1000research.20805.1.Porter R.J., Kalla R., Ho G. T. Ulcerative colitis: Recent advances in the understanding of disease pathogenesis. F1000Res. 2020 Apr 24;9: F1000 Faculty Rev-294. doi: 10.12688/f1000research.20805.1.Vakhitov T. Ya., Kudryavtsev I. V., Sall T. S., Lazareva N. M., Kononova S. V., Khavkin A. I., Sitkin S. I. T-helper cell subsets, key cytokines and chemokines in the pathogenesis of inflammatory bowel disease (Part 2). Vopr. prakt. pediatr. (Clinical Practice in Pediatrics). 2021; 16(1): 41-51. (In Russ.) doi: 10.20953/1817-7646-2021-1-41-51.@@ Вахитов Т. Я., Кудрявцев И. В., Салль Т. С. и др. Субпопуляции Т-хелперов, ключевые цитокины и хемокины в патогенезе воспалительных заболеваний кишечника (часть 2). Вопросы практической педиатрии. 2021; 16(1): 41-51.Vakhitov T. Ya., Kudryavtsev I. V., Sall T. S., Lazareva N. M., Kononova S. V., Khavkin A. I., Sitkin S. I. T-helper cell subsets, key cytokines and chemokines in the pathogenesis of inflammatory bowel disease (Part 2). Vopr. prakt. pediatr. (Clinical Practice in Pediatrics). 2021; 16(1): 41-51. (In Russ.) doi: 10.20953/1817-7646-2021-1-41-51.@@ Вахитов Т. Я., Кудрявцев И. В., Салль Т. С. и др. Субпопуляции Т-хелперов, ключевые цитокины и хемокины в патогенезе воспалительных заболеваний кишечника (часть 2). Вопросы практической педиатрии. 2021; 16(1): 41-51.Jodeleit H., Winkelmann P., Caesar J. et al. Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγnull mice reconstituted with human peripheral blood mononuclear cells. Dis Model Mech. 2021 Jan 1;14(1): dmm046995. doi: 10.1242/dmm.046995.Jodeleit H., Winkelmann P., Caesar J. et al. Head-to-head study of oxelumab and adalimumab in a mouse model of ulcerative colitis based on NOD/Scid IL2Rγnull mice reconstituted with human peripheral blood mononuclear cells. Dis Model Mech. 2021 Jan 1;14(1): dmm046995. doi: 10.1242/dmm.046995.Tyler C. J., Guzman M., Lundborg L. R. et al. Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis. Mucosal Immunol. 2022 Jan;15(1):109-119. doi: 10.1038/s41385-021-00445-z.Tyler C. J., Guzman M., Lundborg L. R. et al. Antibody secreting cells are critically dependent on integrin α4β7/MAdCAM-1 for intestinal recruitment and control of the microbiota during chronic colitis. Mucosal Immunol. 2022 Jan;15(1):109-119. doi: 10.1038/s41385-021-00445-z.Chaudhary C. L., Gurung P., Jang S. et al. Synthesis, activity and mechanism of alkoxy-, carbamato-, sulfonamido-, thioureido-, and ureido-derivatives of 2,4,5-trimethylpyridin-3-ol against inflammatory bowel disease. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1-20. doi: 10.1080/14756366.2019.Chaudhary C. L., Gurung P., Jang S. et al. Synthesis, activity and mechanism of alkoxy-, carbamato-, sulfonamido-, thioureido-, and ureido-derivatives of 2,4,5-trimethylpyridin-3-ol against inflammatory bowel disease. J Enzyme Inhib Med Chem. 2020 Dec;35(1):1-20. doi: 10.1080/14756366.2019.Register of medicines of Russia RLS Encyclopedia of medicines. (in Russ.) Available at: https://www.rlsnet.ru/active-substance/vedolizumab-3616?ysclid=lb511b80y7934578827 Access: 01.05.2023.@@ Регистр лекарственных средств России РЛС Энциклопедия лекарств: https://www.rlsnet.ru/active-substance/vedolizumab-3616?ysclid=lb511b80y7934578827Register of medicines of Russia RLS Encyclopedia of medicines. (in Russ.) Available at: https://www.rlsnet.ru/active-substance/vedolizumab-3616?ysclid=lb511b80y7934578827 Access: 01.05.2023.@@ Регистр лекарственных средств России РЛС Энциклопедия лекарств: https://www.rlsnet.ru/active-substance/vedolizumab-3616?ysclid=lb511b80y7934578827Ailamazyan A. N. The role of signaling molecules in pathogenesis of gastrointestinal tract diseases: optimization of diagnostics and target therapy. Molecular medicine. 2013;(5): 3-7. (in Russ.)@@ Айламазян А. Н. Роль сигнальных молекул в патогенезе заболеваний желудочно-кишечного тракта: оптимизация диагностики и трагетной терапии. Молекулярная медицина. 2013; 5: 3-7.Ailamazyan A. N. The role of signaling molecules in pathogenesis of gastrointestinal tract diseases: optimization of diagnostics and target therapy. Molecular medicine. 2013;(5): 3-7. (in Russ.)@@ Айламазян А. Н. Роль сигнальных молекул в патогенезе заболеваний желудочно-кишечного тракта: оптимизация диагностики и трагетной терапии. Молекулярная медицина. 2013; 5: 3-7.Roosenboom B., van Lochem E. G., Meijer J. et al. Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis. Cells. 2020 Apr 6;9(4):891. doi: 10.3390/cells9040891.Roosenboom B., van Lochem E. G., Meijer J. et al. Development of Mucosal PNAd+ and MAdCAM-1+ Venules during Disease Course in Ulcerative Colitis. Cells. 2020 Apr 6;9(4):891. doi: 10.3390/cells9040891.Ahluwalia B., Moraes L., Magnusson M. K., Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018 Apr;53(4):379-389. doi: 10.1080/00365521.2018.1447597.Ahluwalia B., Moraes L., Magnusson M. K., Öhman L. Immunopathogenesis of inflammatory bowel disease and mechanisms of biological therapies. Scand J Gastroenterol. 2018 Apr;53(4):379-389. doi: 10.1080/00365521.2018.1447597.Castro-Dopico T., Colombel J. F., Mehandru S. Targeting B cells for inflammatory bowel disease treatment: back to the future. Curr Opin Pharmacol. 2020 Dec;55:90-98. doi: 10.1016/j.coph.2020.10.002.Castro-Dopico T., Colombel J. F., Mehandru S. Targeting B cells for inflammatory bowel disease treatment: back to the future. Curr Opin Pharmacol. 2020 Dec;55:90-98. doi: 10.1016/j.coph.2020.10.002.Wang, X., Hao, Gl., Wang, By. et al. Function and dysfunction of plasma cells in intestine. Cell Biosci. 2019 Mar 13;9:26. doi: 10.1186/s13578-019-0288-9.Wang, X., Hao, Gl., Wang, By. et al. Function and dysfunction of plasma cells in intestine. Cell Biosci. 2019 Mar 13;9:26. doi: 10.1186/s13578-019-0288-9.Junhui Z., Guixiu S. Lymphocyte infiltration and key differentially expressed genes in the ulcerative colitis. Medicine (Baltimore). 2020 Aug 28;99(35): e21997. doi: 10.1097/MD.0000000000021997.Junhui Z., Guixiu S. Lymphocyte infiltration and key differentially expressed genes in the ulcerative colitis. Medicine (Baltimore). 2020 Aug 28;99(35): e21997. doi: 10.1097/MD.0000000000021997.Sun X., Huang Y., Zhang Y. L., Qiao D., Dai Y. C. Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells. World J Gastroenterol. 2020 Dec 28;26(48):7593-7602. doi: 10.3748/wjg.v26.i48.7593.Sun X., Huang Y., Zhang Y. L., Qiao D., Dai Y. C. Research advances of vasoactive intestinal peptide in the pathogenesis of ulcerative colitis by regulating interleukin-10 expression in regulatory B cells. World J Gastroenterol. 2020 Dec 28;26(48):7593-7602. doi: 10.3748/wjg.v26.i48.7593.Pararasa C., Zhang N., Tull T. J. et al. Reduced CD27-IgD- B Cells in Blood and Raised CD27-IgD- B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel Disease. Front Immunol. 2019 Mar 5;10:361. doi: 10.3389/fimmu.2019.00361.Pararasa C., Zhang N., Tull T. J. et al. Reduced CD27-IgD- B Cells in Blood and Raised CD27-IgD- B Cells in Gut-Associated Lymphoid Tissue in Inflammatory Bowel Disease. Front Immunol. 2019 Mar 5;10:361. doi: 10.3389/fimmu.2019.00361.Letizia M., Kaufmann U., Wang Y-H. et al. Store-Operated Calcium Entry Controls Innate and Adaptive Immune Cell Function in Inflammatory Bowel Disease. EMBO Mol Med. 2022 Sep 7;14(9): e15687. doi: 10.15252/emmm.202215687.Letizia M., Kaufmann U., Wang Y-H. et al. Store-Operated Calcium Entry Controls Innate and Adaptive Immune Cell Function in Inflammatory Bowel Disease. EMBO Mol Med. 2022 Sep 7;14(9): e15687. doi: 10.15252/emmm.202215687.Rabe H., Malmquist M., Barkman C. et al. Distinct patterns of naive, activated and memory T and B cells in blood of patients with ulcerative colitis or Crohn’s disease. Clin Exp Immunol. 2019 Jul;197(1):111-129. doi: 10.1111/cei.13294.Rabe H., Malmquist M., Barkman C. et al. Distinct patterns of naive, activated and memory T and B cells in blood of patients with ulcerative colitis or Crohn’s disease. Clin Exp Immunol. 2019 Jul;197(1):111-129. doi: 10.1111/cei.13294.Preisker S, Brethack A. K., Bokemeyer A. et al. Crohn’s Disease Patients in Remission Display an Enhanced Intestinal IgM+ B Cell Count in Concert with a Strong Activation of the Intestinal Complement System. Cells. 2019 Jan 21;8(1):78. doi: 10.3390/cells8010078.Preisker S, Brethack A. K., Bokemeyer A. et al. Crohn’s Disease Patients in Remission Display an Enhanced Intestinal IgM+ B Cell Count in Concert with a Strong Activation of the Intestinal Complement System. Cells. 2019 Jan 21;8(1):78. doi: 10.3390/cells8010078.Fu Y., Wang Z., Yu B. et al.Intestinal CD11b+ B Cells Ameliorate Colitis by Secreting Immunoglobulin A. Front Immunol. 2021 Nov 3;12:697725. doi: 10.3389/fimmu.2021.697725.Fu Y., Wang Z., Yu B. et al.Intestinal CD11b+ B Cells Ameliorate Colitis by Secreting Immunoglobulin A. Front Immunol. 2021 Nov 3;12:697725. doi: 10.3389/fimmu.2021.697725.Degasperi G. R. Mucosal Immunology in the Inflammatory Bowel Diseases, Biological Therapy for Inflammatory Bowel Disease.IntechOpen. 2020. doi: 10.5772/intechopen.90037.Degasperi G. R. Mucosal Immunology in the Inflammatory Bowel Diseases, Biological Therapy for Inflammatory Bowel Disease.IntechOpen. 2020. doi: 10.5772/intechopen.90037.Kumric M., Zivkovic P. M., Kurir T. T. et al. Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease. Diagnostics (Basel). 2021 Dec 27;12(1):45. doi: 10.3390/diagnostics12010045.Kumric M., Zivkovic P. M., Kurir T. T. et al. Role of B-Cell Activating Factor (BAFF) in Inflammatory Bowel Disease. Diagnostics (Basel). 2021 Dec 27;12(1):45. doi: 10.3390/diagnostics12010045.Breedveld A., van Egmond M. IgA and FcαRI: Pathological Roles and Therapeutic Opportunities. Front Immunol. 2019 Mar 22;10:553. doi: 10.3389/fimmu.2019.00553.Breedveld A., van Egmond M. IgA and FcαRI: Pathological Roles and Therapeutic Opportunities. Front Immunol. 2019 Mar 22;10:553. doi: 10.3389/fimmu.2019.00553.Wei H., Wang J-Y. Role of Polymeric Immunoglobulin Receptor in IgA and IgM Transcytosis.Int J Mol Sci. 2021 Feb 25;22(5):2284. doi: 10.3390/ijms22052284.Wei H., Wang J-Y. Role of Polymeric Immunoglobulin Receptor in IgA and IgM Transcytosis.Int J Mol Sci. 2021 Feb 25;22(5):2284. doi: 10.3390/ijms22052284.Hansen, I.S., Baeten, D.L.P., den Dunnen, J. The inflammatory function of human Ig A. Cell Mol Life Sci. 2019 Mar;76(6):1041-1055. doi: 10.1007/s00018-018-2976-8.Hansen, I.S., Baeten, D.L.P., den Dunnen, J. The inflammatory function of human Ig A. Cell Mol Life Sci. 2019 Mar;76(6):1041-1055. doi: 10.1007/s00018-018-2976-8.Fransen F., Zagato E., Mazzini E., et al. BALB/c and C57BL/6 mice differ in polyreactive IgA abundance, which impacts the generation of antigen-specific IgA and microbiota diversity. Immunity. 2015 Sep 15;43(3):527-40. doi: 10.1016/j.immuni.2015.08.011.Fransen F., Zagato E., Mazzini E., et al. BALB/c and C57BL/6 mice differ in polyreactive IgA abundance, which impacts the generation of antigen-specific IgA and microbiota diversity. Immunity. 2015 Sep 15;43(3):527-40. doi: 10.1016/j.immuni.2015.08.011.López-García L., Castro-Manrreza M.E. TNF-α and IFN-γ Participate in Improving the Immunoregulatory Capacity of Mesenchymal Stem/Stromal Cells: Importance of Cell-Cell Contact and Extracellular Vesicles.Int J Mol Sci. 2021 Sep 2;22(17):9531. doi: 10.3390/ijms22179531.López-García L., Castro-Manrreza M.E. TNF-α and IFN-γ Participate in Improving the Immunoregulatory Capacity of Mesenchymal Stem/Stromal Cells: Importance of Cell-Cell Contact and Extracellular Vesicles.Int J Mol Sci. 2021 Sep 2;22(17):9531. doi: 10.3390/ijms22179531.Baumgart D. C. Crohn’s disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. Second Edition. Berlin, Germany: Springer, 2017. doi: 10.1007/978-3-319-33703-6.Baumgart D. C. Crohn’s disease and Ulcerative Colitis: From Epidemiology and Immunobiology to a Rational Diagnostic and Therapeutic Approach. Second Edition. Berlin, Germany: Springer, 2017. doi: 10.1007/978-3-319-33703-6.Komban, R.J., Strömberg, A., Biram, A. et al. Activated Peyerös patch B cells sample antigen directly from M cells in the subepithelial dome. Nat Commun. 2019 Jun 3;10(1):2423. doi: 10.1038/s41467-019-10144-w.Komban, R.J., Strömberg, A., Biram, A. et al. Activated Peyerös patch B cells sample antigen directly from M cells in the subepithelial dome. Nat Commun. 2019 Jun 3;10(1):2423. doi: 10.1038/s41467-019-10144-w.Keppler S. J., Goess M. C. Heinze J. M. The Wanderings of Gut-Derived IgA Plasma Cells: Impact on Systemic Immune Responses. Front Immunol. 2021 Apr 15;12:670290. doi: 10.3389/fimmu.2021.670290.Keppler S. J., Goess M. C. Heinze J. M. The Wanderings of Gut-Derived IgA Plasma Cells: Impact on Systemic Immune Responses. Front Immunol. 2021 Apr 15;12:670290. doi: 10.3389/fimmu.2021.670290.Cupi M. L., Sarra M., Marafini I. et al. Plasma Cells in the Mucosa of Patients with Inflammatory Bowel Disease Produce Granzyme B and Possess Cytotoxic Activities. J Immunol. 2014 Jun 15;192(12):6083-91. doi: 10.4049/jimmunol.1302238.Cupi M. L., Sarra M., Marafini I. et al. Plasma Cells in the Mucosa of Patients with Inflammatory Bowel Disease Produce Granzyme B and Possess Cytotoxic Activities. J Immunol. 2014 Jun 15;192(12):6083-91. doi: 10.4049/jimmunol.1302238.Karlsen T. H., Folseraas T., Thorburn D., Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017 Dec;67(6):1298-1323. doi: 10.1016/j.jhep.2017.07.022.Karlsen T. H., Folseraas T., Thorburn D., Vesterhus M. Primary sclerosing cholangitis - a comprehensive review. J Hepatol. 2017 Dec;67(6):1298-1323. doi: 10.1016/j.jhep.2017.07.022.Manganis C. D., Chapman R. W., Culver E. L. Review of primary sclerosing cholangitis with increased IgG4 levels. World J Gastroenterol. 2020 Jun 21;26(23):3126-3144. doi: 10.3748/wjg.v26.i23.3126.Manganis C. D., Chapman R. W., Culver E. L. Review of primary sclerosing cholangitis with increased IgG4 levels. World J Gastroenterol. 2020 Jun 21;26(23):3126-3144. doi: 10.3748/wjg.v26.i23.3126.Seril D. N., Shen B. Diagnosis and Management of IgG4-associated Pouchitis. Practical Gastroenterology. 2014;(9):67-79.Seril D. N., Shen B. Diagnosis and Management of IgG4-associated Pouchitis. Practical Gastroenterology. 2014;(9):67-79.Olpin J. D., Sjoberg B. P., Stilwill S. E. et al. Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease. Radiographics. 2017 Jul-Aug;37(4):1135-1160. doi: 10.1148/rg.2017160121.Olpin J. D., Sjoberg B. P., Stilwill S. E. et al. Beyond the Bowel: Extraintestinal Manifestations of Inflammatory Bowel Disease. Radiographics. 2017 Jul-Aug;37(4):1135-1160. doi: 10.1148/rg.2017160121.Arato A., Savilahti E. IgG3 and IgG4 cells are increased in active ulcerative colitis. Digestion. 1990;47(1):35-41. doi: 10.1159/000200474.Arato A., Savilahti E. IgG3 and IgG4 cells are increased in active ulcerative colitis. Digestion. 1990;47(1):35-41. doi: 10.1159/000200474.Zinöcker M. K., Lindseth I. A. The Western Diet-Microbiome-Host Interaction and Its Role in Metabolic Disease. Nutrients. 2018 Mar 17;10(3):365. doi: 10.3390/nu10030365.Zinöcker M. K., Lindseth I. A. The Western Diet-Microbiome-Host Interaction and Its Role in Metabolic Disease. Nutrients. 2018 Mar 17;10(3):365. doi: 10.3390/nu10030365.Singh S., Dulai P. S., Zarrinpar A. et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):110-121. doi: 10.1038/nrgastro.2016.181.Singh S., Dulai P. S., Zarrinpar A. et al. Obesity in IBD: epidemiology, pathogenesis, disease course and treatment outcomes. Nat Rev Gastroenterol Hepatol. 2017 Feb;14(2):110-121. doi: 10.1038/nrgastro.2016.181.Park S., Kang Y., Koh H., Kim S. Increasing incidence of inflammatory bowel disease in children and adolescents: significance of environmental factors. Clin Exp Pediatr. 2020 Sep;63(9):337-344. doi: 10.3345/cep.2019.00500.Park S., Kang Y., Koh H., Kim S. Increasing incidence of inflammatory bowel disease in children and adolescents: significance of environmental factors. Clin Exp Pediatr. 2020 Sep;63(9):337-344. doi: 10.3345/cep.2019.00500.Jodeleit H., Milchram L., Soldo R. et al. Autoantibodies as diagnostic markers and potential drivers of inflammation in ulcerative colitis. PLoS One. 2020 Feb 12;15(2): e0228615. doi: 10.1371/journal.pone.0228615.Jodeleit H., Milchram L., Soldo R. et al. Autoantibodies as diagnostic markers and potential drivers of inflammation in ulcerative colitis. PLoS One. 2020 Feb 12;15(2): e0228615. doi: 10.1371/journal.pone.0228615.Stepanov Y., Tarasova T., Stoikevych M. et al. The study of tissue IgG4 in the mucous membrane of the colon in patients with inflammatory bowel disease. Gastroenterology. 2021; 55(4): 246-251. doi: 10.22141/2308-2097.55.4.2021.247916.Stepanov Y., Tarasova T., Stoikevych M. et al. The study of tissue IgG4 in the mucous membrane of the colon in patients with inflammatory bowel disease. Gastroenterology. 2021; 55(4): 246-251. doi: 10.22141/2308-2097.55.4.2021.247916.Song D. J., Jun S., Min Hu C. et al. Association of Serum Immunoglobulins Levels With Specific Disease Phenotypes of Crohn’s Disease: A Multicenter Analysis in China. Front Med (Lausanne). 2021 Apr 28;8:621337. doi: 10.3389/fmed.2021.621337.Song D. J., Jun S., Min Hu C. et al. Association of Serum Immunoglobulins Levels With Specific Disease Phenotypes of Crohn’s Disease: A Multicenter Analysis in China. Front Med (Lausanne). 2021 Apr 28;8:621337. doi: 10.3389/fmed.2021.621337.Markmann C., Bhoj V. G. On the road to eliminating long-lived plasma cells-”are we there yet?”. Immunol Rev. 2021 Sep;303(1):154-167. doi: 10.1111/imr.13015.Markmann C., Bhoj V. G. On the road to eliminating long-lived plasma cells-”are we there yet?”. Immunol Rev. 2021 Sep;303(1):154-167. doi: 10.1111/imr.13015.Restellini S., Afif W. Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease. J Clin Med. 2021 Mar 17;10(6):1242. doi: 10.3390/jcm10061242.Restellini S., Afif W. Update on TDM (Therapeutic Drug Monitoring) with Ustekinumab, Vedolizumab and Tofacitinib in Inflammatory Bowel Disease. J Clin Med. 2021 Mar 17;10(6):1242. doi: 10.3390/jcm10061242.Abrahama B., Glassner K. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. Curr Opin Gastroenterol. 2021 Jul 1;37(4):344-350. doi: 10.1097/MOG.0000000000000738.Abrahama B., Glassner K. Positioning biologics and small molecules in the management of moderate to severe ulcerative colitis. Curr Opin Gastroenterol. 2021 Jul 1;37(4):344-350. doi: 10.1097/MOG.0000000000000738.Sandborn W. J., Rebuck R., Wang Y. et al. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 Mar;20(3):578-590.e4. doi: 10.1016/j.cgh.2021.02.025.Sandborn W. J., Rebuck R., Wang Y. et al. Five-Year Efficacy and Safety of Ustekinumab Treatment in Crohn’s Disease: The IM-UNITI Trial. Clin Gastroenterol Hepatol. 2022 Mar;20(3):578-590.e4. doi: 10.1016/j.cgh.2021.02.025.Bamias G., Cominelli F. Exploring the Early Phase of Crohn’s Disease. Clin Gastroenterol Hepatol. 2021 Dec;19(12):2469-2480. doi: 10.1016/j.cgh.2020.09.023.Bamias G., Cominelli F. Exploring the Early Phase of Crohn’s Disease. Clin Gastroenterol Hepatol. 2021 Dec;19(12):2469-2480. doi: 10.1016/j.cgh.2020.09.023.

The authors declare that there are no conflicts of interest present.